Skip to main content

Super navigation

  • Newsroom
    • The Latest
    • Press releases
    • argenx Stories
    • Downloadable assets
A
A

Main navigation additional

  • Home
  • Contact us
  • Home
  • Patients
    • Our commitment
    • Disease areas
    • Patient stories
    • MyRealWorld MG
    • Clinical trials
    • Patient access
    • Resources
  • Pipeline
    • Our pipeline
    • Partnered programs
    • Publications
  • Innovation
    • Science of collaboration
    • IIP
    • Case studies
    • Academic collaborators
    • Antibody engineering
    • Partnering opportunities
  • Products
  • Investors
    • Stock information
    • Events & Presentations
    • Financial reports
    • Shareholder meetings
    • Corporate governance
    • AFM filings
    • SEC filings
    • Analyst coverage
  • Careers
    • Dare to do more
    • Join argenx
    • Benefits
    • Employee stories
  • Newsroom
    • The Latest
    • argenx stories
    • Press releases
    • Downloadable assets
  • About
    • One Team
    • Values
    • Management Team
    • Board of Directors
    • Grants
    • Ethics and Responsibility
    • Contact us
Home

Secondary navigation additional

  • Contact

Secondary/mobile navigation

  • Home
  • Patients
    • Our commitment
    • Disease areas
    • Patient stories
    • MyRealWorld MG
    • Clinical trials
    • Patient access
    • Resources
  • Pipeline
    • Our pipeline
    • Partnered programs
    • Publications
  • Innovation
    • Science of collaboration
    • IIP
    • Case studies
    • Academic collaborators
    • Antibody engineering
    • Partnering opportunities
  • Products
  • Investors
    • Stock information
    • Events & Presentations
    • Financial reports
    • Shareholder meetings
    • Corporate governance
    • AFM filings
    • SEC filings
    • Analyst coverage
  • Careers
    • Dare to do more
    • Join argenx
    • Benefits
    • Employee stories
  • Newsroom
    • The Latest
    • argenx stories
    • Press releases
    • Downloadable assets
  • About
    • One Team
    • Values
    • Management Team
    • Board of Directors
    • Grants
    • Ethics and Responsibility
    • Contact us

Breadcrumb

  1. Home
  2. Investors
  3. AFM filings

AFM filings

 

March 21, 2022
Annual Report 2021
March 31, 2021
Annual Report 2020
May 28, 2020
Summary Document
May 28, 2020
Summary Document - Dutch Translation
May 28, 2020
Securities Note
May 28, 2020
Amendment to Universal Registration Document
September 20, 2018
Admission to listing and trading of new ordinary shares
March 26, 2018
Registration Document
April 22, 2017
Admission to listing and trading of new ordinary shares
June 2, 2016
Registration Document
May 31, 2016
Listing of shares on Euronext Brussels
June 20, 2014
Initial Offering of Shares
TwitterFacebookLinkedInWhatsApp
Home
  • Home
  • Contact us

Footer navigation

  • Home
  • Patients
    • Our commitment
    • Disease areas
    • Patient stories
    • MyRealWorld MG
    • Clinical trials
    • Patient access
    • Resources
  • Pipeline
    • Our pipeline
    • Partnered programs
    • Publications
  • Innovation
    • Science of collaboration
    • IIP
    • Case studies
    • Academic collaborators
    • Antibody engineering
    • Partnering opportunities
  • Products
  • Investors
    • Stock information
    • Events & Presentations
    • Financial reports
    • Shareholder meetings
    • Corporate governance
    • AFM filings
    • SEC filings
    • Analyst coverage
  • Careers
    • Dare to do more
    • Join argenx
    • Benefits
    • Employee stories
  • Newsroom
    • The Latest
    • argenx stories
    • Press releases
    • Downloadable assets
  • About
    • One Team
    • Values
    • Management Team
    • Board of Directors
    • Grants
    • Ethics and Responsibility
    • Contact us
2023 © argenx
Disclaimer
Privacy policy
Regulations